Correction: Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial.

Authors

Philip Mease, Providence St. Joseph HealthFollow
A Kavanaugh
A Reimold

Document Type

Response or Comment

Publication Date

9-7-2018

Publication Title

RMD Open

Clinical Institute

Orthopedics & Sports Medicine

Department

Rheumatology

Department

Orthopedics

Comments

This corrects the article "Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial" DOI: 10.1136/rmdopen-2018-000723

Recommended Citation

Mease, Philip; Kavanaugh, A; and Reimold, A, "Correction: Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial." (2018). Articles, Abstracts, and Reports. 1022.
https://digitalcommons.providence.org/publications/1022